High-dose chemotherapy for the treatment of breast and ovarian cancer

Current Opinion in Oncology

Volumn 9, Issue 2, 1997, Pages 122-125

  Cagnoni, Pablo J ^a   Shpall, Elizabeth J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MITOXANTRONE; PACLITAXEL; THIOTEPA;

BREAST CANCER; CANCER CHEMOTHERAPY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL; HUMAN; KIDNEY FAILURE; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; SHORT SURVEY; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR CELL;

EID: 0031011271     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199703000-00003     Document Type: Short Survey

References (32)

1. Peters WP: High-dose chemotherapy for breast cancer. In The Breast. Edited by Harris JR, Lippman ME, Morrow M, Hellman S. Philadelphia: Lippincott-Raven; 1996:735-743.
2. Cagnoni PJ, Shpall EJ: High-dose chemotherapy for the treatment of breast cancer. In The Clinical Practice of Stem Cell Transplantation. Edited by Barrett J Treleaven J, Oxford: Isis Medical Media Ltd; 1997:in press.
3. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995, 13:2483-2489. The only published randomized trial comparing high-dose chemotherapy with conventional chemotherapy in metastatic breast cancer.
4. Bearman SI, Overmoyer BA, Bolwell BG, Mechling BE, Taylor CW, Jones RB, Shpall EJ, Ross M, Cagnoni PJ: High-dose chemotherapy with autologous peripheral blood progenitor cells for primary breast cancer in patients with 4-9 involved axillary lymph nodes: a feasibility study [abstract], Proc Am Soc Clinical Oncol 1996, 15:959.
5. Hudis C, Seidman A, Raptis G, et al.: Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience. Semin Oncol 1996, 23:58-64.
6. Ayash L, Antman K, Wheeler C, et al.: High-dose multi-modality therapy with autologous stem cell support for stage IIIB breast cancer: the DFCI/BIH experience [abstract]. Proc Am Soc Clin Oncol 1995, 14:318.
7. Franklin WA, Shpall EJ, Archer P, et al.: Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous stem cell support. Breast Cancer Res Treat 1996, 41:1-13. Demonstrates the usefulness of immunocytochemistry to detect breast cancer cells in autologous grafts.
8. Vredenburgh J, Silva O, de Sombre K, et al.: The significance of bone marrow micrometastases for patients with breast cancer and > 10+ lymph nodes treated with high-dose chemotherapy and hematopoietic support. Proc Am Soc Clin Oncol 1995, 14:317a.
9. Fields KK, Elfenbein GJ, Trudeau WL, et al.: Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996, 14:1868-1876. This work suggests that the presence or absence of breast cancer cells in the graft has prognostic significance.
10. Fields KK, Elfenbein GJ, Lazarus HM, et al.: Maximum-tolerated doses of ifosfamide, carboplatin and etoposide given over 6 days followed by autologous stem-cell resuce: toxicity profile. J Clin Oncol 1995, 13:323-332.
11. Perkins JB, Fields KK, Elfenbein GJ: Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. Semin Oncol 1995, 2:5-8.
12. Klumpp TR, Mangan KF, Glenn LD, et al.: Phase II pilot study of high-dose busulfan and CY followed by autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993, 11:337-339.
13. Kalaycioglu ME, Lichtin AE, Anderson SW, et al.: High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue from metastatic breast cancer. Am J Clin Oncol 1995, 17:491-494.
14. Stemmer SM, Cagnoni PJ, Shpall EJ, et al.: High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor cell support: a phase I trial. J Clin Oncol 1996, 14:1463-1472. This paper demonstrates the feasibility of incorporating paclitaxel into a high-dose chemotherapy regimen.
15. Rowinsky EK, Citardi MJ, Noe DA, et al.: Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol 1993, 119:727-733.
16. Rowinsky EK, Donehower RC, Jones RJ, et al.: Microtubule changes and cytotoxicity in leukemic cell lines treated with Taxol. Cancer Research 1988, 48:4093-4100.
17. Milad L, Hunter NR, Kurdoglu B, et al.: Kinetics of mitotic arrest and apoptosis in murine mammary and ovarian tumors teated with Taxol. Cancer Chemother Pharmacol 1995, 35:297-303.
18. McCloskey DE, Davidson NE: Paclitaxel-induced programmed cell death in human breast cancer cells [abstract]. Proc Am Assoc Cancer Res 1995, 36:416.
19. Cagnoni PJ, Shpall EJ, Bearman SI, et al.: Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. Semin Oncol 1996, 23(suppl 6):43-48.
20. Somlo G, Doroshow JH, Forman SJ, et al.: High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 1994, 73:1678-1685. Demonstrated in this paper is the feasibility of incorporating doxorubicin into a high-dose chemotherapy regimen.
21. Dunphy FR, Spitzer G, Buzdar AU, et al.: Treatment of estrogen receptor negative or hormonally refractory breast cancer with double high-dose chemotherapy for intensification and bone marrow support. J Clin Oncol 1990, 8:1207-1216.
22. Ayash LJ, ELias A, Wheeler C, et al.: Double dose-intensive chemotherapy with autologous marrow and peripheral blood progenitor cell support for metastatic breast cancer: a feasibility study. J Clin Oncol 1994, 12:37-44.
23. Bitran JD, Samuels B, Klein L, et al.: Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yield prolonged survival in stage IV breast cancer. Bone Marrow Transplant 1996, 17:157-162.
24. Rodenhuis S, Westerman A, Holtkamp MJ, et al.: Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol 1996, 14:1473-1483.
25. Ghalie R, Williams SF, Valentino LA, et al.: Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant 1995, 1:40-46.
26. Vahdat L, Raptis G, Fennelly D, et al.: Rapidly cycled course of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res 1995, 1:1267-1273.
27. Dunphy FR, Spitzer G, Rossiter Fornoff JE, et al.: Factors predicting long-term survival for metastatic breast cancer patients related with high-dose chemotherapy and bone marrow support. Cancer 1994, 73:2157-2167.
28. Somlo G, Doroshow J, Forman S, et al.: High-dose chemotherapy and stem cell rescue for the treatment of primary high-risk breast cancer: prognostic indicators of overall survival and progression-free survival [abstract]. Proc Am Soc Clin Oncol 1995, 14:113.
29. Doroshow J, Somlo G, Ahn C, et al.: Prognostic factors predicting progression-free and overall survival in patients with responsive metastatic breast cancer treated with high-dose chemotherapy and bone stem cell reinfusion [abstract]. Proc Am Soc Clin Oncol 1995, 14:319.
30. Ayash LJ, Wheeler C, Fairclough D, et al.: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995, 13:2043-2049.
31. Bitran JD, Samuels B, Trujillo Y, et al.: Her2/neu over experssion is associated with treatment failure in women with high-risk stage II and stage IIIA breast cancer (> 10 involved lymph nodes) treated with high-dose chemotherapy and autologous hematopoietic progenitor cell support following standard-dose adjuvant chemotherapy. Clin Cancer Res 1996, 2:1509-1513. First report about the possible importance of Her2/neu as a prognostic factor in patients who undergo high-dose chemotherapy.
32. Stiff PJ, Bayer R, Kerger C, et al.: High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients. J Clin Oncol 1997, in press. Largest single-center experience of ovarian cancer patients treated with high-dose chemotherapy, with detailed analysis of prognostic factors.